Table 5.

Factors Associated with Day 28 CR/PR, 6 Month Mortality and TRM: Multivariate Analysis

Factors	N	Odds Ratio of day 28 CR/PR (95% CI)	P	Relative Risk of Mortality (95% CI)	P	Relative Risk of TRM (95% CI)	P
Age
<20*	421	1.0		1.0		1.0
21–40**	459	0.8 (0.6–1.1)	0.10	1.3 (1.0–1.8)	0.03	1.6 (1.2–2.1)	0.004
41+	843	0.8 (0.6–1.1)	0.15	1.7 (1.3–2.3)	<0.001	2.4 (1.8–3.3)	<0.001
Disease Risk†
Standard*	812	1.0		1.0		1.0
High	717	1.1 (0.9–1.4)	0.45	1.2 (1.0–1.5)	0.05	1.1 (0.9–1.3)	0.52
Non–malignant	191	0.9 (0.6–1.3)	0.47	1.06 (0.8–1.5)	0.74	1.8 (1.3–2.5)	0.001
Conditioning Regimen
Myeloablative*	1273	1.0		1.0		1.0
Reduced Intensity	450	1.2 (0.9–1.6)	0.24	1.0 (0.8–1.2)	0.78	0.9 (0.6–1.1)	0.25
Donor Type
Matched Sibling*	598	1.0		1.0		1.0
Other related	73	0.9 (0.5–1.5)	0.62	1.5 (1.0–2.2)	0.07	1.6 (1.0–2.6)	0.42
Matched URD	626	0.7 (0.6–0.9)	0.01	1.5 (1.2–1.8)	<0.001	1.6 (1.2–2.0)	<0.001
Mismatched URD	164	0.3 (0.2–0.5)	<0.001	2.2 (1.6–2.9)	<0.001	2.4 (1.7–3.2)	<0.001
UCB	262	0.9 (0.7–1.3)	0.45	1.1 (0.8–1.4)	0.67	1.0 (0.7–1.4)	0.81
Days from HCT to Initial Steroid Rx
<28 days*	717	1.0		1.0		1.0
≥28 days	1006	1.2 (1.0–1.5)	0.06	0.8 (0.7–0.9)	0.006	0.8 (0.7–1.0)	0.02
GVHD Risk††
Standard Risk*	1454	1.0		1.0		1.0
High Risk	269	0.3 (0.2–0.4)	<0.001	2.1 (1.7–2.6)	<0.001	2.5 (2.0–3.2)	<0.001

^*reference group

^**comparison of 21–40 vs. 41+: for CR/PR, P=0.27; for mortality, P=0.02; for TRM, P<0.001.

^†Standard-risk indicates acute leukemia in CR1 or CR2, CML in first chronic phase, MDS without excess blasts, or non-malignant disease. High risk indicates all others.

^††As defined in Table 3 with Standard Risk = single organ involvement (stage 1–3 skin or stage 1–2 GI) or two organ involvement (stage 1–3 skin plus stage 1 GI; or stage 1–3 skin plus stage 1–4 liver). All other patients are High Risk.